Abstract
The French RCT CLOSE demonstrated that patients having experienced cryptogenic stroke and having a patent foramen ovale (PFO) with echocardiographic features representing risk of stroke benefited from PFO closure compared to antiplatelet therapy. This analysis determines the cost-effectiveness from the perspective of the French healthcare system of percutaneous PFO closure in combination with antiplatelet therapy versus antiplatelet therapy alone using economic data collected during the CLOSE trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
